- Home
- BIIB
BIIB
Biogen Inc.
as 01-14-2025 4:00pm EST
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
| Founded: | 1978 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 22.2B | IPO Year: | 1991 |
| Target Price: | $234.79 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 11.06 | EPS Growth: | 10.05 |
| 52 Week Low/High: | $142.42 - $252.17 | Next Earning Date: | 02-11-2025 |
| Revenue: | $9,607,500,000 | Revenue Growth: | -3.86% |
| Revenue Growth (this year): | -0.04% | Revenue Growth (next year): | -1.17% |
Latest Biogen Inc. News
BIIB Breaking Stock News: Dive into BIIB Ticker-Specific Updates for Smart Investing
TipRanks
16 hours ago
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
TipRanks
16 hours ago
Biogen bid for Sage does not change narrative, says BMO Capital
Benzinga
17 hours ago
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
Pharmaceutical Technology
18 hours ago
Eisai and Biogen’s subcutaneous Leqembi set for FDA review
MT Newswires
a day ago
Biogen, Eisai Say Biologics License Application for Leqembi Accepted by US FDA
GlobeNewswire
a day ago
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
Pharmaceutical Technology
a day ago
Biogen proposes acquisition of partner Sage Therapeutics
Zacks
a day ago
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
Compare BIIB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIIB Biogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.